Table 1.
CCSA patient characteristics, treatment outcome and availability of the archival tumor tissue used in this exploratory study.
| Study SeqID | Gender/ Age (Years) |
Origin of Tested Material | MET Status (EORTC 90101 Protocol) | Best Response (RECIST) | Progression Status on Crizotinib | PFS (Months) | Survival Status | OS (Months) | Exploratory Study | |
|---|---|---|---|---|---|---|---|---|---|---|
| Status | FISH (% Positive Cells) | |||||||||
| 5 | M/28 | P | MET+ | nd | not reached | Progression | 0.7 | Dead | 0.7 | IHC |
| 12 | F/55 | P | MET+ | 70 | SD | Progression | 2.6 | Dead | 2.6 | IHC + Seq |
| 13 | M/33 | P | MET− | 10 | PD | Progression | 2.2 | Dead | 12.1 | IHC + Seq |
| 20 | M/38 | Meta | MET+ | 90 | PD | Progression | 1.4 | Dead | 4.4 | Seq |
| 21 | M/22 | P | MET+ | 61 | PD | Progression | 1.1 | Dead | 2.1 | IHC |
| 23 | M/55 | P | MET+ | nd | SD | Progression | 2.8 | Dead | 14.5 | IHC + Seq |
| 25 | M/29 | Meta | MET+ | 71 | SD | Progression | 4.3 | Dead | 7.6 | IHC |
| 32 | M/44 | P | MET+ | 59 | SD | Progression | 4.3 | Dead | 7.6 | IHC + Seq |
| 35 | M/52 | Meta | MET+ | 71 | SD | Progression | 9.0 | Dead | 10.8 | IHC + Seq |
| 36 | M/29 | Meta | MET+ | 85 | SD | Progression | 8.3 | Dead | 21.7 | IHC + Seq |
| 49 | F/23 | Meta | MET+ | 71 | PD | Progression | 0.8 | Dead | 1.4 | IHC |
| 52 | M/40 | P | MET+ | 40 | PD | Progression | 0.8 | Dead | 4.4 | IHC + Seq |
| 57 | F/38 | Meta | MET+ | 86 | SD | Progression | 4.8 | Alive | 14.5 | IHC + Seq |
| 60 | F/54 | P | MET+ | 73 | not reached | Progression | 9.2 | Dead | 9.2 | IHC + Seq |
| 68 | M/44 | P | MET+ | 87 | SD | Progression | 5.5 | Dead | 16.8 | IHC + Seq |
| 69 | M/43 | P | MET- | 0 | SD | Progression | 4.2 | Alive | 20.7 | IHC + Seq |
| 72 | F/41 | Meta | MET+ | 85 | SD | Progression | 2.7 | Dead | 8.5 | IHC |
| 81 | M/32 | P | MET+ | 81 | SD | Progression | 11.3 | Dead | 11.3 | IHC |
| 91 | M/57 | P | MET+ | 23 | PD | Progression | 1.4 | Dead | 7.6 | IHC |
| 101 | M/17 | P | MET+ | 31 | not reached | Progression | 1.5 | Dead | 1.5 | IHC + Seq |
| 106 | nd | P | MET+ | 75 | not treated | nd | nd | Alive | nd | IHC + Seq |
| 112 | F/56 | P | MET+ | 78 | PR | No progression | 30.6 | Alive | 30.6 | IHC + Seq |
| 115 | F/30 | P | MET+ | 92 | SD | No progression | 26.3 | Alive | 26.3 | IHC + Seq |
| 121 | M/33 | Meta | MET+ | 96 | SD | Progression | 7.7 | Dead | 14.0 | IHC + Seq |
| 123 | M/50 | P | MET+ | 84 | SD | Progression | 9.6 | Dead | 15.4 | IHC + Seq |
| 124 | F/31 | P | nd | nd | not reached | Progression | 0.8 | Dead | 0.8 | IHC |
| 126 | F/47 | Meta | MET+ | 67 | SD | Progression | 2.8 | Dead | 8.1 | IHC + Seq |
| 127 | nd | P | MET+ | 68 | PD | Progression | 1.4 | Alive | 1.4 | Seq |
| 135 | M/50 | P | MET+ | 73 | SD | Progression | 5.1 | Dead | 9.4 | IHC + Seq |
| 141 | F/49 | Meta | MET+ | 72 | not reached | Progression | 2.4 | Dead | 2.4 | IHC + Seq |
| 144 | F/28 | n/a | MET+ | 60 | not reached | Progression | 0.9 | Dead | 0.9 | IHC |
| 145 | M/62 | Meta | MET+ | 34 | PD | Progression | 1.6 | Dead | 8.0 | IHC |
| 146 | M/56 | Meta | MET+ | 71 | SD | Progression | 9.1 | Dead | 9.1 | IHC + Seq |
| 147 | nd | P | MET− | 0 | not treated | nd | nd | Alive | nd | IHC + Seq |
+: positive, −: negative, F: female, FISH: fluorescent in situ hybridization, IHC: immunohistochemistry, M: male, Meta: metastatic lesion, nd: no data, OS: overall survival, P: primary tumor, PD: progressive disease, PFS: progression-free survival, PR: partial response, RECIST: Response Evaluation Criteria in Solid Tumors, SD: stable disease and Seq: sequencing.